Abu Dhabi Biobank’s Paul Downey on why biobanking is becoming critical healthcare infrastructure
As the Abu Dhabi Biobank moves from launch into full-scale operation, its GM explains how the initiative is set to reshape precision medicine, clinical research and the future of healthcare in the UAE
12 May, 2026
TT
16
At Make it in the Emirates 2026, Abu Dhabi’s new agreement with Japanese partners on advanced therapies highlighted how quickly the emirate is moving to strengthen the foundations needed for next-generation healthcare.
That conversation inevitably leads to the newly launched Abu Dhabi Biobank, developed through a strategic partnership between Department of Health – Abu Dhabi and M42. While biobanks have traditionally been viewed as research support systems, Abu Dhabi is positioning this one as something far more strategic, linking biospecimens, genomic sequencing, clinical records and real-world health data to power precision medicine, advanced therapies and preventative healthcare.
The broader ambition is to shorten the path between scientific discovery and real-world treatment while building the foundations of a stronger life sciences ecosystem in Abu Dhabi.
Speaking to Gulf Business on the sidelines of the event, Paul Downey, GM Abu Dhabi Biobank, explains why biobanking is increasingly being treated as national healthcare infrastructure, how the Japan partnership could support local manufacturing of advanced therapies, and why Abu Dhabi believes its diverse population data can give it a meaningful edge in global healthcare innovation.
Abu Dhabi is positioning the Abu Dhabi Biobank as more than a research tool. Why is biobanking now being treated as long-term national infrastructure for healthcare?
Modern biobanking is no longer a support function behind research. It is foundational infrastructure for healthcare systems seeking to advance precision medicine, preventive care, and next-generation therapeutics. To understand disease at a population level, countries need biobanks that operate at scale, with strong governance and deep integration across healthcare systems.
Developed through a strategic partnership between the Department of Health – Abu Dhabi (DoH) and M42, the Abu Dhabi Biobank is more than a repository of samples. We are creating a nationally governed platform that connects biological materials with genomic, clinical, and real-world data. This enables researchers, clinicians, and industry partners to move more efficiently from discovery to application. In this model, a biobank becomes a strategic national asset that strengthens healthcare delivery, supports scientific advancement, and drives growth across the life sciences ecosystem.
Countries that lead the next era of healthcare will be those investing early in this kind of capability. Abu Dhabi recognizes that long-term leadership depends on building the infrastructure that enables better science and ultimately better patient outcomes.
The biobank links biological samples with genomic, clinical and lifestyle data. What diseases or health challenges do you expect it to impact first — cancer, rare diseases, diabetes, organ transplants, or preventative healthcare?
The earliest and most immediate impact will likely be in chronic, non-communicable diseases, where the regional burden is high and precision-based approaches have the potential to meaningfully improve outcomes. However, the value of Abu Dhabi Biobank extends far beyond any single disease area. Its infrastructure is designed to support a wide range of health challenges through a more intelligent and data-driven approach.
In oncology, rare diseases, transplant research, and prevention healthcare, integrating biospecimens with genomic and clinical data enables more precise diagnosis and better insight into local disease patterns and the development of more targeted interventions.
While some areas are likely to advance more quickly than others, the larger shift is far more significant. Abu Dhabi is building the capability to move beyond healthcare models based on generalized assumptions drawn from other populations and instead develop strategies and prevention approaches informed by the realities of its own diverse population. That is where meaningful long-term impact begins, and where true healthcare transformation becomes possible.
Abu Dhabi recently signed an agreement with Japanese partners at Make it in the Emirates 2026 focused on advanced therapies. How does that partnership help shorten the path between scientific discovery and real-world patient treatment?
The significance of this partnership is that it connects the pieces that are too often fragmented in healthcare innovation. It shortens the path because it brings discovery, data, translational infrastructure and clinical development into one connected model. Too often, healthcare innovation breaks down because the chain is fragmented – you have promising science in one place, manufacturing somewhere else, data elsewhere, and no efficient pathway into patient care. This partnership is important because it helps close these gaps.
Abu Dhabi Biobank contributes the biological materials, the integrated data environment, the governance, the clinical trial facilitation, and the translational infrastructure. Human Life CORD brings proprietary UC-MSC technology and serious clinical development expertise. When these capabilities are combined, we create a direct route toward validated, clinically relevant therapies that can be developed around actual patient need in this region.
The real value is not more research, but faster translation from discovery to treatment. In advanced therapies, innovation only matters when it reaches patients.

Could the Japan tie-up help Abu Dhabi move beyond research into local manufacturing of advanced therapies such as cell and gene treatments, and reduce reliance on overseas supply chains?
Yes, and that is one of the most important outcomes of this agreement. The partnership establishes one of the UAE’s first localised GMP manufacturing and clinical translation pathways for umbilical cord mesenchymal stem cell therapies, strengthening Abu Dhabi’s advanced therapy capabilities.
For years, many countries have relied on imported innovation. Abu Dhabi is taking a different approach by building local capabilities across development, translation, and manufacturing. This is important because advanced therapies are highly dependent on speed, quality control, logistics, and cost. Reducing reliance on overseas supply chains strengthens resilience and improves access.
With residents from more than 200 nationalities, Abu Dhabi has access to highly diverse health data. How significant is that in addressing global gaps in genomic and clinical research?
One of the biggest challenges in global genomic and clinical research is that many datasets still do not reflect the full diversity of the world’s populations. As a result, precision medicine is often less accurate or less effective for underrepresented groups. Abu Dhabi has an opportunity to help address that imbalance.
What makes the emirate distinctive is its ability to combine population diversity with high-quality biospecimens and integrated genomic, clinical, and real-world data within a well-governed framework. That creates a much stronger basis for understanding how diseases present across different populations and how therapies can be developed more precisely.
The impact goes beyond the UAE. Regionally, it means better evidence and more relevant healthcare insights for local populations. Globally, it allows Abu Dhabi to help address longstanding representation gaps in health research, giving the biobank scientific value and relevance on an international scale.
Abu Dhabi has ambitions to become a global healthcare and life sciences hub. How does the biobank strengthen its competitiveness in attracting pharmaceutical companies, clinical trials and international research partnerships?
Global pharmaceutical companies and research partners are not looking for ambition alone. They are looking for infrastructure, high-quality data, regulatory clarity, operational readiness, and access to patient populations that can support meaningful research and development. Abu Dhabi Biobank brings those elements together.
Abu Dhabi Biobank integrates biospecimen access, automated cryogenic storage, genomic and clinical data, patient stratification, translational research, and clinical trial support within a nationally governed framework aligned with international standards. That is exactly the kind of environment global partners look for when deciding where to invest and run research programs.
More importantly, it allows Abu Dhabi to compete on capability, not aspiration. It signals that the emirate is building a leading life sciences ecosystem that can support discovery, translation, and advanced manufacturing. That is how you attract long-term partnerships and build global credibility in healthcare.























